Navy SEAL Turned Entrepreneur Takes Aim at Cannabinoid Pharmaceuticals

George Hodgin is leading BRC into new healthcare modalities.

Note: Cannabis Confidential shifted content strategy in 2026 with insights from trusted partners, industry insiders, and thought leaders who’ve got something to say. There will be no more paywalls or content fees; think of it as The Players Tribune for the cannabis industry, with an ethos of honesty, trust and respect.

click here

The exam room was quiet when the Afghanistan combat veteran finally raised his hand and asked the question that he had mulled over for weeks.

He had served in special operations.

He had deployed to combat.

He returned home carrying the weight of chronic pain, opioid dependence, and PTSD; conditions that, taken together, shattered his world such that the idea of his previous life seemed distant, if not foreign.

He had only heard about medical cannabis.

He was skeptical, but he was also out of options.

Unlike his usual self, he had brought a friend with him for support.

He used to always be the one to lend support.

So, he turned to his physician and asked:

“I’m at the end of my rope. I want to use medical marijuana. Can you tell me what to use and where to get it?”

The doctor’s answer was measured, honest, and to his friend, astounding.

“It probably won’t kill you,” the physician said. “But I live in the world of FDA-approved drugs. And that doesn’t exist for medical marijuana.”

The friend in that room was another combat veteran, George Hodgin.

Former Navy SEAL officer.

Stanford MBA graduate.

And from that moment forward, the founder of what would become BRC Therapeutics.

click here to learn more about BRC Therapeutics

“Patients deserve better,” Hodgin says today, from his office in Monterey County, CA.

“Patients deserve FDA-approved therapeutics that meet the rigorous quality and safety standards of any other drug. That moment made it undeniable. We had to address this. We had to build a company to make this a reality.”

To understand why George Hodgin founded a company to navigate one of the most complex regulatory environments in the pharmaceutical industry, it helps to better understand who this man is.

He grew up in Charlotte, North Carolina, and attended the University of North Carolina at Chapel Hill on a Morehead-Cain Scholarship, one of the oldest and most prestigious merit scholarships in the United States, graduating Phi Beta Kappa.

On September 11th, 2001, he watched the world change.

While most of us were in shock, George decided to answer his call to duty.

Hodgin became a Navy SEAL officer, deploying to combat in Afghanistan and other countries around the world.

The SEAL community is defined by a specific philosophy: when the mission is real and the stakes are high, quitting isn’t an option.

You improvise, you adapt, and you overcome.

That same guiding principle has underpinned BRC’s progress to date.

While advancing a misunderstood treatment modality and navigating complex technical challenges, we meet regulatory uncertainty head on and keep going.

After his military service, Hodgin earned an MBA from Stanford Graduate School of Business.

While completing his studies in 2017, a fellow special operations veteran needed someone to sit with him at doctor’s appointments; someone who understood what he had been through and could help him advocate for himself.

SEALs, who often traverse long distances in the cold and dark waters overseas, call that type of friend a swim buddy.

This spirit is reflected in how Hodgin leads and empowers his team at BRC, and this spirit helps explain their devotion to patients.

Hodgin assembled a team of experts in drug development and manufacturing along with others who have helped him carry his mission towards providing much-needed treatments to patients.

The United States is facing a chronic pain crisis.

Tens of millions of Americans suffer from conditions for which existing treatments offer only partial relief, carry serious risks, or both.

The opioid epidemic is, in many ways, the consequence of a medical system that tried to solve a complex biological problem with a blunt solution.

The consequences have been profound.

Meanwhile, for decades, patients and physicians have observed that cannabinoids appear to have therapeutic potential across a wide range of neurological conditions and pain syndromes.

Extracts directly derived from the cannabis plant appear to have particularly strong potency, especially if containing more than one compound.

The anecdotal evidence has become increasingly difficult to dismiss.

The evidence, real world and peer-reviewed, continues to build.

And yet the medical community has been left in an impossible position: without FDA-approved treatments, physicians cannot prescribe, recommend dosing, or confidently stand behind botanical cannabinoid medicines with any clinical authority.

The gap between what patients experience and what medicine could legitimately offer is not just scientific, it’s simply rooted in regulatory barriers and the realities of drug development.

Advancing botanical cannabinoid therapeutics through the full FDA drug approval process is both time-consuming and resource intensive.

From its founding, BRC Therapeutics has been built on two core principles: complete regulatory compliance from the ground up, combined with the scientific and manufacturing rigor that patients and physicians deserve.

This is more than a compliance posture.

It is a deliberate scientific and commercial strategy.

BRC has been registered with the DEA for five years and adheres to federal law.

That federal compliance infrastructure is not an end in itself.

It is the foundation for something distinct within this modality: developing a pipeline of cannabinoid-based therapeutics and shepherding them through the FDA approval process, with every stage supported by the manufacturing standards, clinical evidence, and the substantiated claims physicians need to prescribe them with confidence.

The scientific foundation of BRC Therapeutics rests on a concept that is straightforward in theory but has proven elusive in practice: multimodality.

Many of the most intractable conditions in medicine like chronic pain, neurological disorders and inflammatory conditions, are multi-mechanistic.

This means that they do not arise from a single biological pathway, but from the interplay of nervous and immune systems, with both central and peripheral mechanisms contributing.

This complexity is precisely what single-target drugs have failed to adequately address.

It’s widely recognized that cannabinoids are inherently multimodal, engaging multiple receptors, ion channels, and signaling pathways in parallel.

BRC’s proprietary drug candidates are defined combinations of botanically derived cannabinoids, formulated at specific ratios to maximize efficacy and minimize adverse effects.

They are not products sold to consumers.

They are investigational therapies engineered to pharmaceutical standards and manufactured in accordance with current Good Manufacturing Practice (cGMP) and Good Agricultural and Collection Practices (GACP), with the goal of advancing toward regulatory approval.

“Traditional therapeutics often target a single receptor or pathway, frequently leaving gaps in treatment,” the company states. “BRC’s therapies are designed to address multiple mechanisms both within and beyond the nervous system, potentially offering a more comprehensive approach to care.”

Several of BRC Therapeutics’ investigational drug candidates are currently being evaluated in clinical trials, targeting conditions where patients have long been underserved by existing medicine.

BRC’s pipeline extends into neurological and movement disorders, areas where the company’s multimodal approach may offer advantages given the complexity of the underlying disease biology.

Creating commercially viable drugs within an underappreciated modality is not a new concept.

The history of modern medicine is filled with breakthroughs that once began as overlooked or misunderstood compounds or were championed by scientists long before the pharmaceutical industry caught up—psychedelics, monoclonal antibodies, recombinant proteins, RNA, and live biotherapeutics just to name a few.

BRC’s view is that by applying the same standard and discipline expected of any drug development program, cannabinoid therapeutics can follow a similar trajectory, and position BRC to further define and spearhead the field.

GW Pharmaceuticals proved the concept. In 2018, the FDA approved Epidiolex® (cannabidiol), a plant-derived, highly purified single active molecule formulation for the treatment of rare pediatric epilepsies.

In doing so, the company established that a cannabis-derived drug could earn full FDA approval and garner commercial success.

GW Pharma was subsequently acquired by Jazz Pharmaceuticals for approximately $7.2 billion. Annual revenues from Epidiolex exceed $1 billion.

BRC Therapeutics is not seeking to replicate GW.

It is building what comes next: a broader approach, a deeper pipeline, and a scalable model for how botanically derived cannabinoid therapeutics can systematically address underserved conditions where multi-mechanistic diseases have outpaced the capabilities of existing treatments.

A phrase on the BRC website captures what their work is about: Live. Every. Day.

It reflects a focus not just on symptom management, but on restoring consistency and function to patients’ lives.

For those living with chronic conditions, the promise is not occasional relief, but the ability to live fully, every day.

Hodgin is careful to draw a sharp line between what BRC is doing and what has come before in the broader cannabis space.

This is not a wellness company.

It is not a dispensary.

It is not a CBD brand or a THC product dressed up in clinical language.

It is a drug development company, operating within the same regulatory framework, held to the same standards and clinical rigor as any serious pharmaceutical enterprise.

“The medical community didn’t have the answers we were looking for,” Hodgin says of those early experiences.

“There was simply no effective treatment available at the time that had been held to those standards and could reliably be used to treat the indications my friend was seeking relief for. We’re well on our way to change that.”

This is third-party content and does not constitute advice or a recommendation.